Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Oncocontraception

  • Chapter
  • First Online:
Contraception for the Medically Challenging Patient

  • 1037 Accesses

Abstract

Over 700,000 women in the United States are diagnosed with cancer each year. Nearly 17 % of women with cancer are within the reproductive age. With improvements in treatments and prognosis, quality of life factors are increasing in importance for these women. Reproductive health is an important quality of life indicator. Focus on oncofertility has overshadowed other aspects of reproductive health including sexuality and oncocontraception. In this chapter we focus on the multiple facets of oncocontraception. While cancer treatments may alter fertility significantly, in the absence of reliable markers of fertility, contraception is paramount to reduce the risk of an unintended pregnancy. Cancer survivors are less likely to be offered effective contraception, if offered at all. Models of conceptualizing contraception are outlined as well as strategies to implement oncocontraception within oncologic care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. De Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561–70.

    Article  PubMed Central  PubMed  Google Scholar 

  2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013.

    Google Scholar 

  3. American Cancer Society. Breast cancer facts & figures 2013–2014. Atlanta, GA: American Cancer Society Inc.; 2013.

    Google Scholar 

  4. Howlader NNA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, et al., editors. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 1975–2013.

    Google Scholar 

  5. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–83.

    Article  PubMed  Google Scholar 

  6. Schover LR. Sexuality and fertility after cancer. Hematol Am Soc Hematol Educ Progr. 2005;2005:523–7.

    Article  Google Scholar 

  7. Valle J, Clemons M, Hayes S, Fallowfield L, Howell A. Contraceptive use by women receiving chemotherapy for breast cancer. Breast. 1998;7:143–9.

    Article  Google Scholar 

  8. Knapp CA, Quinn GP, Rapalo D, Woodworth L. Patient provider communication and reproductive health. Adv Exp Med Biol. 2012;732:175–85.

    Article  PubMed  Google Scholar 

  9. Quinn GP, Vadaparampil ST. Fertility preservation and adolescent/young adult cancer patients: physician communication challenges. J Adolesc Health. 2009;44:394–400.

    Article  PubMed  Google Scholar 

  10. Mitwally MF. Management of reproductive needs in cancer patients: clinical perspectives. Expert Rev Anticancer Ther. 2008;8:1589–95.

    Article  PubMed  Google Scholar 

  11. Schwarz EB, Lohr PA, Gold MA, Gerbert B. Prevalence and correlates of ambivalence towards pregnancy among nonpregnant women. Contraception. 2007;75:305–10.

    Article  PubMed  Google Scholar 

  12. Patel AA, Mini S, Sutaria RP, Schoenhage MB, Patel AR, Radeke EK, et al. Reproductive health issues in women with cancer. J Oncol Pract. 2008;4:101–5.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Murphy D, Klosky JL, Termuhlen A, Sawczyn KK, Quinn GP. The need for reproductive and sexual health discussions with adolescent and young adult cancer patients. Contraception. 2013;88:215–20.

    Article  PubMed  Google Scholar 

  14. Patel A, Sreedevi M, Malapati R, Sutaria R, Schoenhage MB, Patel AR, et al. Reproductive health assessment for women with cancer: a pilot study. Am J Obstet Gynecol. 2009;201:191e1-4.

    Google Scholar 

  15. Patel A, Schwarz EB. Cancer and contraception: release date May 2012 SFP guideline #20121. Contraception. 2012;86:191–8.

    Article  PubMed  Google Scholar 

  16. Laurence V, Rousset-Jablonski C. Contraception and cancer treatment in young persons. Adv Exp Med Biol. 2012;732:41–60.

    Article  PubMed  Google Scholar 

  17. Canada AL, Schover LR. Research promoting better patient education on reproductive health after cancer. J Natl Cancer Inst Monogr. 2005;2005:98–100.

    Article  Google Scholar 

  18. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.

    Article  PubMed  Google Scholar 

  19. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83:1622–8.

    Article  Google Scholar 

  20. Guttmacher Institute. Contraceptive needs and services: national and state data, 2008 update. New York: Guttmacher Institute; 2010.

    Google Scholar 

  21. St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. Diabetes Care. 1993;16:1572–8.

    Article  CAS  PubMed  Google Scholar 

  22. Holing EV, Beyer CS, Brown ZA, Connell FA. Why don't women with diabetes plan their pregnancies? Diabetes Care. 1998;21:889–95.

    Article  CAS  PubMed  Google Scholar 

  23. Schwarz EB, Maselli J, Gonzales R. Contraceptive counseling of diabetic women of reproductive age. Obstet Gynecol. 2006;107:1070–4.

    Article  PubMed  Google Scholar 

  24. Chuang CH, Chase GA, Bensyl DM, Weisman CS. Contraceptive use by diabetic and obese women. Womens Health Issues. 2005;15:167–73.

    Article  PubMed  Google Scholar 

  25. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010. MMW Rep 2010;59.

    Google Scholar 

  26. Association of Reproductive Health Professionals (ARHP). Choosing a birth control method, 2011. Washington, DC: Association of Reproductive Health Professionals; 2011. p. 2011.

    Google Scholar 

  27. Schwarz EB, Hess R, Trussell J. Contraception for cancer survivors. J Gen Intern Med. 2009;24 Suppl 2:S401–6.

    Article  PubMed  Google Scholar 

  28. Helewa M, Levesque P, Provencher D, Lea RH, Rosolowich V, Shapiro HM. Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can. 2002;24:164–80. quiz 81-4.

    PubMed  Google Scholar 

  29. Cvancarova M, Samuelsen SO, Magelssen H, Fossa SD. Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol. 2009;27:334–43.

    Article  PubMed  Google Scholar 

  30. Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 1987;317:1315–21.

    Article  CAS  PubMed  Google Scholar 

  31. Del Mastro L, Catzeddu T, Venturini M. Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev. 2006;32:417–22.

    Article  PubMed  Google Scholar 

  32. Chasle S, How CC. The effect of cytotoxic chemotherapy on female fertility. Eur J Oncol Nurs. 2003;7:91–8.

    Article  PubMed  Google Scholar 

  33. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009;24:982–90.

    Article  CAS  PubMed  Google Scholar 

  34. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005;11:69–89.

    Article  PubMed  Google Scholar 

  35. Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril. 2010;94:2824–7.

    Article  CAS  PubMed  Google Scholar 

  36. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116:592–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Rosendahl M, Andersen CY, La Cour Freiesleben N, Juul A, Lossl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010;94:156–66.

    Article  CAS  PubMed  Google Scholar 

  38. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6:229–39.

    Article  CAS  PubMed  Google Scholar 

  39. Abdallah RT, Muasher SJ. Surviving cancer, saving fertility-the promise of cryopreservation. Sexuality, reproduction and menopause. Sex Reprod Menopause. 2006;4:7–12.

    Article  Google Scholar 

  40. Sönmezer M, Aytaç R, Demirel LC, Kurtay G. Mesenteric vein thrombosis in a pregnant patient heterozygous for the factor V (1691 G –>A) Leiden mutation. Eur J Obstet Gynecol Reprod Biol. 2004;114:234–5.

    PubMed  Google Scholar 

  41. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998;27:927–43.

    Article  CAS  PubMed  Google Scholar 

  42. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–92.

    CAS  PubMed  Google Scholar 

  43. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.

    CAS  PubMed  Google Scholar 

  44. Lamb MA. Effects of chemotherapy on fertility in long-term survivors. Dimens Oncol Nurs. 1991;5:13–6.

    CAS  PubMed  Google Scholar 

  45. Longhi A, Macchiagodena M, Vitali G, Bacci G. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25:292–6.

    Article  PubMed  Google Scholar 

  46. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin. 2005;55:211–28. quiz 63-4.

    Article  PubMed  Google Scholar 

  47. Administration FD, editor. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register 2008;23. http://federalregister.gov/r/0910-AF11.

  48. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546–54.

    Article  PubMed  Google Scholar 

  49. Delaware AstraZeneca Pharmaceuticals. NOLVADEX (Tamoxifen Citrate) [package insert]. Wilmington, DE: Delaware AstraZeneca Pharmaceuticals LP; 2004.

    Google Scholar 

  50. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.

    Article  Google Scholar 

  51. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging. 2008;8:135–45.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994;343:1318–21.

    Article  CAS  PubMed  Google Scholar 

  54. Halakivi-Clarke L, Cho E, Onojafe I, Liao DJ, Clarke R. Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res. 2000;6:305–8.

    CAS  PubMed  Google Scholar 

  55. Steinkellner A, Chen W, Denison SE. Adherence to oral contraception in women on category X medications. Am J Med. 2010;123:929–34e1.

    Article  PubMed  Google Scholar 

  56. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med. 2007;147:370–6.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Takeda Pharmaceutical Company Limited. LUPRON DEPOT® (leuprolide acetate for depot suspension) [package insert]. Osaka: Takeda Pharmaceutical Company Limited; 2012.

    Google Scholar 

  59. Fossa SD, Dahl AA. Fertility and sexuality in young cancer survivors who have adult-onset malignancies. Hematol Oncol Clin North Am. 2008;22:291–303, vii.

    Article  PubMed  Google Scholar 

  60. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt). 2009;18:311–9.

    Article  Google Scholar 

  61. Celgene Corporation. Celgene risk evaluation and mitigation strategy. Berkeley Heights, NJ: Celgene Corporation; 2013.

    Google Scholar 

  62. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7:394–403.

    Article  CAS  PubMed  Google Scholar 

  63. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18:117–21.

    Article  CAS  PubMed  Google Scholar 

  64. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7:535–43.

    Article  CAS  PubMed  Google Scholar 

  65. Lishner M. Cancer in pregnancy. Ann Oncol. 2003;14 Suppl 3:31–6.

    Google Scholar 

  66. Daniels K, Mosher WD, Jones J. Contraceptive methods women have ever used: United States, 1982–2010. National health statistics reports, no 62. Hyattsville, MD: National Center for Health Statistics; 1982–2010. p. 2013.

    Google Scholar 

  67. American College of Obstetricians, Gynecologists Committee on Gynecologic Practice, Long-Acting Reversible Contraception Working Group. ACOG Committee opinion no. 450: increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2009;114:1434–8.

    Article  Google Scholar 

  68. ACOG. ACOG practice bulletin no. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.

    Article  Google Scholar 

  69. Bartz D, Greenberg JA. Sterilization in the United States. Rev Obstet Gynecol. 2008;1:23–32.

    PubMed Central  PubMed  Google Scholar 

  70. Smith GL, Taylor GP, Smith KF. Comparative risks and costs of male and female sterilization. Am J Public Health. 1985;75:370–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Laurence V, Gbolade BA, Morgan SJ, Glaser A. Contraception for teenagers and young adults with cancer. Eur J Cancer. 2004;40:2705–16.

    Article  CAS  PubMed  Google Scholar 

  72. Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107:1634–41.

    Article  CAS  PubMed  Google Scholar 

  73. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16:696–701.

    Article  CAS  PubMed  Google Scholar 

  74. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton 3rd LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.

    Article  CAS  PubMed  Google Scholar 

  75. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17–21.

    PubMed  Google Scholar 

  76. Zapata LB, Whiteman MK, Marchbanks PA, Curtis KM. Intrauterine device use among women with ovarian cancer: a systematic review. Contraception. 2010;82:38–40.

    Article  PubMed  Google Scholar 

  77. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34 Suppl 1:S3–18.

    Article  CAS  PubMed  Google Scholar 

  78. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30:763–75.

    Article  CAS  PubMed  Google Scholar 

  79. Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception. 2011;83:218–22.

    Article  CAS  PubMed  Google Scholar 

  80. Pongsatha S, Ekmahachai M, Suntornlimsiri N, Morakote N, Chaovisitsaree S. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years. Int J Gynaecol Obstet. 2010;109:223–5.

    Article  CAS  PubMed  Google Scholar 

  81. Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF, Fernandes AM, Monteiro I, Bahamondes L. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. Reprod Health. 2007;4:11.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum Reprod. 2006;21:466–70.

    Article  CAS  PubMed  Google Scholar 

  83. Bhalla AK. Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol. 2010;24:313–27.

    Article  PubMed  Google Scholar 

  84. Sim LA, McGovern L, Elamin MB, Swiglo BA, Erwin PJ, Montori VM. Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. Int J Eat Disord. 2010;43:218–25.

    PubMed  Google Scholar 

  85. Martinez G, Daniels K, Chandra A. Fertility of men and women aged 15–44 years in the United States: National Survey of Family Growth. Natl Health Stat Report. 2006–2010;2012:1–28.

    Google Scholar 

  86. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84:363–7.

    Article  CAS  PubMed  Google Scholar 

  87. Jadav SP, Parmar DM. Ulipristal acetate, a progesterone receptor modulator for emergency contraception. J Pharmacol Pharmacother. 2012;3:109–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev. 2004;2004:Cd001324.

    Google Scholar 

  89. Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002;187:1070–80.

    Article  PubMed  Google Scholar 

  90. Winther JF, Boice Jr JD, Svendsen AL, Frederiksen K, Olsen JH. Induced abortions in Danish cancer survivors: a population-based cohort study. J Natl Cancer Inst. 2009;101:687–9.

    Article  PubMed Central  PubMed  Google Scholar 

  91. Barrett HL, Lust K, Callaway LK, Fagermo N, Portmann C. Termination of pregnancy for maternal medical indications: failings in delivery of contraceptive advice? Aust N Z J Obstet Gynaecol. 2011;51:532–5.

    Article  PubMed  Google Scholar 

  92. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol. 2013;121:943–50.

    Article  CAS  PubMed  Google Scholar 

  93. Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000;356:1711–7.

    Article  CAS  PubMed  Google Scholar 

  94. FFPRHC. FFPRHC guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care. 2004;30:99–108. quiz 09.

    Article  Google Scholar 

  95. ACOG. Practice ACoOaGCoG ACOG committee opinion. No 337: noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol. 2006;107:1479–82.

    Article  Google Scholar 

  96. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90:17–22.

    Article  CAS  PubMed  Google Scholar 

  97. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Poststerilization regret: findings from the United States collaborative review of sterilization. Obstet Gynecol. 1999;93:889–95.

    Article  CAS  PubMed  Google Scholar 

  98. Hirshfeld-Cytron J, Winter J. Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis. Am J Obstet Gynecol. 2013;209:56.e1–6.

    PubMed  Google Scholar 

  99. Teva Women’s Health, Inc. ParaGard® T 380A intrauterine copper contraceptive [package insert]. Sellersville, PA: Teva Women’s Health, Inc; 2013.

    Google Scholar 

  100. Correia L, Ramos AB, Machado AI, Rosa D, Marques C. Magnetic resonance imaging and gynecological devices. Contraception. 2012;85:538–43.

    Article  PubMed  Google Scholar 

  101. Zieman M, Kanal E. Copper T380A IUD and magnetic resonance imaging. Contraception. 2007;75:93–5.

    Article  CAS  PubMed  Google Scholar 

  102. Emans SJ, Grace E, Woods ER, Smith DE, Klein K, Merola J. Adolescents' compliance with the use of oral contraceptives. JAMA. 1987;257:3377–81.

    Article  CAS  PubMed  Google Scholar 

  103. Patel A, Radeke EK, Uy A, Zaren HA. Reproductive health algorithm. J Clin Oncol. 2011;29(Suppl 27; Abstr 263).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Family Planning Services, Department of Obstetrics and Gynecology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA

    Ashlesha Patel M.D., M.P.H., Alicia Roston M.P.H., Kelly Stempinski M.P.H., Lindsay Zimmerman M.P.H & Erica O’Neill M.D., M.P.H.

  2. Rush Medical College, Chicago, IL, USA

    Ashok R. Patel M.D.

Authors
  1. Ashlesha Patel M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Roston M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly Stempinski M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lindsay Zimmerman M.P.H
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erica O’Neill M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ashok R. Patel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashlesha Patel M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

    Rebecca H. Allen

  2. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA

    Carrie A. Cwiak

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Patel, A., Roston, A., Stempinski, K., Zimmerman, L., O’Neill, E., Patel, A.R. (2014). Oncocontraception. In: Allen, R., Cwiak, C. (eds) Contraception for the Medically Challenging Patient. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1233-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1233-9_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1232-2

  • Online ISBN: 978-1-4939-1233-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation